Challenges for chemotherapy in ovarian cancer.

BACKGROUND Ovarian cancer is treated with surgery followed by combination chemotherapy with paclitaxel plus carboplatin. In an effort to improve outcomes, clinical trials are evaluating the following strategies: maintenance therapy; intraperitoneal drug administration; new combinations; novel cytotoxics; combination chemotherapy for recurrent disease; and molecular-targeted therapies. PATIENTS AND METHODS Clinical trials evaluating the above strategies are being performed in ovarian cancer in patients with: (1) previously untreated advanced ovarian cancer; (2) platinum-sensitive recurrent disease; and (3) platinum-resistant recurrent disease. RESULTS Combination chemotherapy regimens are superior to single-agent therapy in recurrent ovarian cancer. Molecular-targeted therapy has produced objective responses in previously treated patients. Maintenance therapy of any type has not been shown to prolong survival. Intraperitoneal therapy has resulted in improved survival with considerable toxicity in patients with small-volume stage III disease. CONCLUSIONS Numerous novel clinical strategies are being evaluated in ovarian cancers that have the potential to improve outcomes compared to standard therapy.

[1]  E. Eisenhauer,et al.  Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. Hampton.  Monoclonal antibody therapies shine in breast cancer clinical trials. , 2005, JAMA.

[3]  Michael W Sill,et al.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  E. Eisenhauer,et al.  Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Pignata,et al.  Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Gore.  Treatment of relapsed epithelial ovarian cancer , 2001 .

[8]  T. Bauknecht,et al.  A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. , 2003, Journal of the National Cancer Institute.

[9]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[10]  M. van Glabbeke,et al.  Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  V. Torri,et al.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial , 2003, The Lancet.

[12]  M. Piccart,et al.  Intraperitoneal cisplatin versus no further treatment: 8‐year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum‐based intravenous chemotherapy , 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[13]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[14]  R. Ozols.  Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Berek,et al.  Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Sabbatini,et al.  A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal, and fallopian tube cancer , 2005 .

[17]  Alan Gordon,et al.  Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. , 2004, Journal of the National Cancer Institute.

[18]  M. Markman.  Point: Intraperitoneal chemotherapy in the management of ovarian cancer. , 2004, Journal of the National Comprehensive Cancer Network : JNCCN.

[19]  E. Eisenhauer,et al.  First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin (TEC) vs paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-NCIC CTG Gynaecological Cancer Intergroup phase III trial , 2002 .

[20]  D. Alberts,et al.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. , 1996, The New England journal of medicine.

[21]  C. Jackisch,et al.  A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8). , 2005, Gynecologic oncology.

[22]  K. Patel,et al.  Multi‐institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S‐transferase P1‐1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer , 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[23]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, New England Journal of Medicine.

[24]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[25]  B N Bundy,et al.  Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  B. Monk,et al.  A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group (GOG) study , 2008 .

[27]  R. Gray,et al.  Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 , 2005 .

[28]  M. Piccart,et al.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. , 2000, Journal of the National Cancer Institute.

[29]  B. Weber,et al.  Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB-IV. An AGO-GINECO Intergroup phase III trial. , 2004, Journal of Clinical Oncology.

[30]  D. Matei,et al.  Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status , 2005 .

[31]  J. Thigpen.  Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-Line Chemotherapy for Ovarian Carcinoma , 2006 .

[32]  C. Schade-Brittinger,et al.  Paclitaxel/carboplatin (TC) vs. paclitaxel/carboplatin followed by topotecan (TOP) in first-line treatment of advanced ovarian cancer. Mature results of a Gynecologic Cancer Intergroup phase III trial of the AGO OVAR and GINECO , 2005 .

[33]  T. Herzog,et al.  Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. , 2004, Gynecologic oncology.

[34]  G. Hall,et al.  Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study , 2004, British Journal of Cancer.

[35]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[36]  E. Pujade-Lauraine,et al.  Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. Rubin,et al.  Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. Bookman.  Developmental chemotherapy and management of recurrent ovarian cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.